Genmab And Seattle Genetics Progress Cervical Cancer ADC
Topline Phase II data for the antibody-drug conjugate tisotumab vedotin put it on a swift path towards approval in cervical cancer.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The company's CEO talked to Scrip about the expected US launch of tisotumab vedotin likely later in 2021 and the company's partnering strategy going forward.
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.